Neoadjuvant vs perioperative chemo-immunotherapy according to pathological response in resectable non-small cell lung cancer: a reconstructed individual patient data meta-analysis

医学 围手术期 新辅助治疗 佐剂 病态的 阶段(地层学) 肿瘤科 肺癌 免疫疗法 内科学 外科 癌症 生物 古生物学 乳腺癌
作者
A. Nuccio,Fabio Salomone,Alberto Servetto,Biagio Ricciuti,Daniele Marinelli,Alessandra Bulotta,Giulia Veronesi,Marina Chiara Garassino,Valter Torri,Benjamin Besse,Giuseppe Viscardi,Roberto Ferrara
出处
期刊:Journal of the National Cancer Institute [Oxford University Press]
卷期号:117 (11): 2388-2393 被引量:4
标识
DOI:10.1093/jnci/djaf090
摘要

Neoadjuvant chemo-immunotherapy transformed early stage non-small cell lung cancer (NSCLC) treatment. However, the prognostic value of different pathological responses and the impact of adjuvant immunotherapy within a chemotherapy-immunotherapy perioperative strategy remains unclear. We estimated time-to-event outcomes by graphical reconstruction of event-free survival curves by pathological response (major pathological response, no major pathological response) reported in early stage NSCLC neoadjuvant or perioperative chemotherapy-immunotherapy trials. The major pathological response 1%-10% subgroup, previously unreported, was retrieved by removing patients achieving pathological response from the major pathological response group. Survival analysis by pathological response and comparison between neoadjuvant or perioperative strategies within subgroups were assessed. A statistically significant event-free survival difference according to pathological response was found, showing a prognostic gradient shifting from pathological response (good), major pathological response 1%-10% (intermediate), and no major pathological response (poor). There was no difference between neoadjuvant or perioperative strategies within subgroups; however, a trend for event-free survival benefit with perioperative and neoadjuvant chemotherapy-immunotherapy was observed in major pathological response 1%-10% and no major pathological response patients, respectively. In conclusion, a pathological response-based algorithm could better tailor early stage NSCLC treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
听话的傲松完成签到 ,获得积分10
1秒前
1秒前
1秒前
1秒前
科研通AI6.4应助霖壹海海采纳,获得10
2秒前
3秒前
wjf完成签到,获得积分20
3秒前
所所应助坚定的灭龙采纳,获得20
3秒前
3秒前
科研狗完成签到,获得积分10
4秒前
ash_alice发布了新的文献求助10
5秒前
5秒前
czl完成签到,获得积分10
5秒前
悦耳笑晴发布了新的文献求助10
5秒前
zb123完成签到,获得积分10
5秒前
Baywreath发布了新的文献求助10
5秒前
简单延恶发布了新的文献求助10
5秒前
wjf发布了新的文献求助10
5秒前
Orange应助任性的诗兰采纳,获得10
6秒前
6秒前
小蘑菇应助无语的凌瑶采纳,获得10
7秒前
8秒前
张天完成签到,获得积分10
8秒前
柒秒发布了新的文献求助30
9秒前
9秒前
bkagyin应助优秀的怀蕊采纳,获得10
10秒前
10秒前
10秒前
10秒前
11秒前
12秒前
12秒前
12秒前
12秒前
cdercder应助wjf采纳,获得10
13秒前
齐媛媛完成签到,获得积分10
13秒前
Wangyingjie5完成签到,获得积分10
13秒前
13秒前
霸气的冰旋完成签到,获得积分10
13秒前
777完成签到,获得积分10
14秒前
高分求助中
GL 2 A method for assessing the in-place cleanability of food processing equipment, Fourth Edition, December 2023 3000
Annie Ernaux: De la perte au corps glorieux 600
Developing Solid Oral Dosage Forms Pharmaceutical Theory and Practice (3rd Edition) 500
Writing Systems 500
类器官构建与应用:从基础到前沿 500
Thermodynamics of Natural Systems 400
Electric Vehicle Powertrains Design Fundamentals, Components, and Applications 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6814439
求助须知:如何正确求助?哪些是违规求助? 8529604
关于积分的说明 18156499
捐赠科研通 6143380
什么是DOI,文献DOI怎么找? 3030943
邀请新用户注册赠送积分活动 2007720
关于科研通互助平台的介绍 2007715